Skip to main content
. Author manuscript; available in PMC: 2013 Feb 13.
Published in final edited form as: Adv Drug Deliv Rev. 2007 Mar 16;59(2-3):141–152. doi: 10.1016/j.addr.2007.03.008

Figure 3.

Figure 3

(A) Coronal section of autopsy rat brain at 14 days after implantation of C6 rat glioma cells in the caudate-putamen of adult Fischer CD344 rats weighing180–200 g. The C6 cells were permanently transfected with clone 790 plasmid DNA, and produce high levels of luciferase when grown as brain tumors in vivo [33]. (B) The nucleotide sequence and secondary structure of the anti-luciferase shRNA encoded by clone 952 is shown. From [33]. (C) Luciferase (left panel) and γ-glutamyl transpeptidase (GTP, right panel) enzyme activity in C6-790 tumor and contralateral brain in animals treated either with saline or with OX26 MAb-targeted PILs carrying clone 952 plasmid DNA. Enzyme assay measurements were performed at 5 days following the single intravenous injection of saline or RNAi therapeutic. The tumor luciferase activity was no different from the saline treated animals in C6-790 tumor bearing rats treated with OX26 MAb-targeted PILs carrying clone 959 plasmid DNA, where clone 959 is the empty expression plasmid. From [33].